BOSTON--(BUSINESS WIRE)--BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has been named "BioTech AI Company of the Year" in the fourth annual BioTech Breakthrough Awards program, conducted by the Tech Breakthrough Organization, a leading global market intelligence and recognition platform for today’s most competitive categories of technology. Honored as the “Therapeutic Platform of the Year” in 2023 for having drug candidates in multiple late-stage trials, BPGbio was recognized this year for its breakthrough causal AI approach to drug discovery and development, leveraging its powerful NAi Interrogative Biology® Platform.
BPGbio is driving a new era of innovation in the biotech market by combining advanced AI with a biology-first approach, redefining how therapies are discovered and developed. Central to this innovation is the NAi Interrogative Biology® Platform, an AI-driven technology leveraging one of the world’s largest non-governmental biobanks, with over 100,000 clinically annotated and multi-omics annotated patient samples. Powered by causal AI and the world’s fastest supercomputer, Frontier, at Oak Ridge National Laboratory, the platform accelerates the identification of novel drug targets and biomarkers, resulting in an unmatched ability to advance treatments for critical diseases.
"We are incredibly honored to be named BioTech AI Company of the Year," said Niven R. Narain, Ph.D., President & CEO of BPGbio. "At BPGbio, we are dedicated to reimagining biology for humanity by integrating cutting-edge causal AI with biological insights to accelerate drug discovery. This award is a testament to the work our team and collaborators around the world have done to push the boundaries of innovation, enabling us to develop therapies designed to address unmet medical needs and improve patient outcomes."
Unlike some competitors that rely on public data sets or take an AI-first approach, BPGbio’s platform integrates comprehensive multi-omics data from real patient samples, ensuring that its AI outputs are deeply rooted in human biology. This has led to a robust pipeline of late-stage clinical trials in oncology, rare diseases, and neurology for the company.
Key 2024 Milestones for BPGbio:
- Phase 2 Oncology Trials: BPGbio’s BPM31510, a novel CoQ10 lipid nanodispersion, showed significant improvements in survival in Phase 2 trials for pancreatic cancer. An on-going Phase 2b trial for GBM is also progressing well.
- Rare Pediatric Disease Phase 3 Trials: BPGbio is planning a Phase 3 trial for BPM31510, targeting primary CoQ10 deficiency to address unmet medical needs for patients. BPM3150IV for Primary CoQ10 Deficiency and BPM31510T for Epidermolysis Bullosa were respectively granted Rare Pediatric Disease Designations by the FDA recently, marking two Rare Pediatric Disease Designations for the BPM31510 franchise.
- Protein Degradation Breakthrough: BPGbio pioneered its E2-based Targeted Protein Degradation (TPD) program, drugging the long considered undruggable and unlocking new treatments in oncology, cardiology, and neurology with improved efficacy and reduced resistance risks.
- Scientific Contributions: BPGbio’s pioneering work in science include Parkinson’s biomarkers, published in Nature’s Scientific Reports, and new findings on diabetes and fat reduction featured in Nature Communications. Additionally, BPGbio’s high-profile conference presentations further showcase its cutting-edge contributions to advancing research in biotechnology and therapeutic development.
With a biology-first approach and AI-driven innovation, BPGbio is leading the charge in the AI biotech field, accelerating drug discovery and development, reducing costs, and paving the way for more effective and accessible treatments across a range of diseases.
About BPGbio
BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using bespoke Bayesian AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat disease. For more information, visit www.bpgbio.com.
